Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacqueline C Barrientos

Showing results (1-10 of 74) with videos related to

Pageof 8
Sort By:
The Lancet. Oncology|February 25, 2018
Can umbralisib bring PI3Kδ out of the shadows?Jacqueline C Barrientos
Cancer Control : Journal of the Moffitt Cancer Center|December 1, 2015
Management of Chronic Lymphocytic Leukemia in the ElderlyJacqueline C Barrientos
Future Oncology (London, England)|June 22, 2016
Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphomaJacqueline C Barrientos
Oncotargets and Therapy|June 9, 2016
Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potentialJacqueline C Barrientos
Hematology. American Society of Hematology. Education Program|December 4, 2016
Sequencing of chronic lymphocytic leukemia therapiesJacqueline C Barrientos
Oncotargets and Therapy|April 1, 2021
Oral PI3K-δ,γ Inhibitor for the Management of People with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Narrative Review on DuvelisibAnkit Shah, Jacqueline C Barrientos
The New England Journal of Medicine|March 21, 2014
Movement toward optimization of CLL therapyKanti R Rai, Jacqueline C Barrientos
Hematology. American Society of Hematology. Education Program|December 4, 2020
Chemotherapy-free frontline therapy for CLL: is it worth it?Joanna M Rhodes, Jacqueline C Barrientos
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Tailored Treatment Strategies for Chronic Lymphocytic Leukemia in a Rapidly Changing EraDanielle Brander, Prioty Islam, Jacqueline C Barrientos
BMJ Case Reports|November 24, 2024
Refractory immune thrombocytopenic purpura (ITP) secondary to prior COVID-19 infection requiring a splenectomyMoki Hein, Vielka Fernandez, Jacqueline C Barrientos, et al.
Pageof 8

Showing results (1-10 of 74) with videos related to

Sort By:
Pageof 8
The Lancet. Oncology|February 25, 2018
Can umbralisib bring PI3Kδ out of the shadows?Jacqueline C Barrientos
Cancer Control : Journal of the Moffitt Cancer Center|December 1, 2015
Management of Chronic Lymphocytic Leukemia in the ElderlyJacqueline C Barrientos
Future Oncology (London, England)|June 22, 2016
Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphomaJacqueline C Barrientos
Oncotargets and Therapy|June 9, 2016
Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potentialJacqueline C Barrientos
Hematology. American Society of Hematology. Education Program|December 4, 2016
Sequencing of chronic lymphocytic leukemia therapiesJacqueline C Barrientos
Oncotargets and Therapy|April 1, 2021
Oral PI3K-δ,γ Inhibitor for the Management of People with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Narrative Review on DuvelisibAnkit Shah, Jacqueline C Barrientos
The New England Journal of Medicine|March 21, 2014
Movement toward optimization of CLL therapyKanti R Rai, Jacqueline C Barrientos
Hematology. American Society of Hematology. Education Program|December 4, 2020
Chemotherapy-free frontline therapy for CLL: is it worth it?Joanna M Rhodes, Jacqueline C Barrientos
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Tailored Treatment Strategies for Chronic Lymphocytic Leukemia in a Rapidly Changing EraDanielle Brander, Prioty Islam, Jacqueline C Barrientos
BMJ Case Reports|November 24, 2024
Refractory immune thrombocytopenic purpura (ITP) secondary to prior COVID-19 infection requiring a splenectomyMoki Hein, Vielka Fernandez, Jacqueline C Barrientos, et al.
Pageof 8